Clinical observation of intravitreal injection with Bevacizumab for iris neovascularization

王凯,姜燕荣,梁晓莹,黎晓新
2008-01-01
Abstract:Objective To evaluate the efficacy of intravitreal injection with Bevacizumab for iris neovascularization(INV)which caused by proliferative diabetic retinopathy(PDR)or central retinal vein occlusion(CRVO). Methods The clinical data of 39 patients(47 eyes)with INV who undergone intravitreal injection with Bevacizumab from 12,2006 to 3,2007 in Department of Ophthalmology,People's Hospital of Peking University were retrospectively analyzed.The patients(22 males and 17 females,23left eyes and 24 right eyes)aged from 28 to 82 years with the average of(57.77±13.0)years.26 cases (34 eyes)were PDR and 13 cases(13 eyes)were CRVO.All of patients underwent intravitrealinjection with 1.25 mg/0.05 ml Bevacizumab.Follow-up time was 1 day,3 days,1 week,3 weeks and 6 weeks after the treatment.The visual acuity,changes of intraocular pressure and changes of INV before and after the treatment were observed and analyzed. Results In patients with PDR,the visual acuity was improved in 19 eyes(55.9%),was stable in 15 eyes(44.1%)and none decreased.In patients with CRVO,the visual acuity was improved in 4 eyes(30.8%),was stable in 9 eyes(69.0%)and none decreased.Among neovascular glaucoma(NVG),decrease of IOP was noticed in 16 eyes with PDR (80%)and 6 eyes with CRV0(66.7%).Regression of INV was noticed in 97.1%PDR patients and 84.6%CRVO patients. Conclusions Intravitreal injection with Bevacizumab is very effective in treating INV.Further researches still needs to explore long term efficacy,safety and complications of this treatment.
What problem does this paper attempt to address?